AVTR

AvantorF

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$10.20

Analysis reference price unavailable

Analysis 2026-05-05 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$8.80

Analysis reference price unavailable

Analysis 2026-05-05 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$6.60

Analysis reference price unavailable

Analysis 2026-05-05 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-05

AI commentary

Headline tone improved after the April 29 print because results were framed as a beat and guidance was reaffirmed, but the evidence base is still mostly company filings plus a small number of secondary headlines. The May 4 anchor price of $7.99 suggests the post-earnings move did not yet establish a durable rerating, so sentiment looks cautiously improved rather than fully repaired.

RankAlpha Sentiment Codex - 2026-05-05

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-Q1 rerating window after beat framing and FY2026 guidance reaffirmationMedium impact

Avantor's April 29 earnings release said first-quarter results exceeded management expectations, reported net sales of $1.581 billion, adjusted EPS of $0.17, and reaffirmed FY2026 guidance; the near-term setup is whether that better-than-feared print can hold after the initial positive reaction. [#8-K-2026-04-29]

2026-08-03eventOrganic growth remains the gating metric for the next operating proof pointHigh impact

The same Q1 release showed a 4.1% organic sales decline, with VWR organic sales down 4.8% and Bioscience and Medtech Products down 2.0%; if the next update does not show clearer volume recovery, the market can fade the guidance reaffirmation. [#8-K-2026-04-29]

2026-12-31catalystTurnaround and deleveraging need another leg of proofHigh impact

Management highlighted improved execution in Bioscience and Medtech Products and stabilization in VWR, while Q1 debt fell to $3.816 billion from $3.946 billion at year-end and adjusted net leverage was 3.3x; sustained cash conversion and further debt reduction would matter for a rerating, but this still looks like an execution-monitoring story rather than a clean inflection. [#10-Q-2026-04-29]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-05 • Updated nightlySource: Internal modelMethodology